# ACCURAY INCORPORATED (ARAY) · Edgar & Edgarette company card

> Accuray Incorporated (ARAY) saw revenue fall 12.3% in FY2026 to $402 million, operating margin -6.6% against a 1.2% median for surgical & medical instruments & apparatus, equity 9.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1138723 · fiscal year ended 2026-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/ARAY) · [JSON](https://www.pops4.com/boards/company/ARAY.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $402M |
| Revenue growth, 1 year | -12.3% |
| Revenue growth per year | -1.7% |
| Operating margin | -6.6% (prior year 1.7%) |
| Net margin | -12.2% |
| Operating cash flow | −$7M |
| Capital spending | $6M |
| Free cash flow | −$13M |
| Cash | $41M |
| Long-term debt | $148M |
| Total assets | $444M |
| Total equity | $42M |
| Equity ÷ assets | 9.4% |
| Return on equity | -118.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -3.04 (distress zone)
- Piotroski F: 1 of 9 (weak)
- Beneish M: -3.06 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · filed earlier statements no longer to be relied on, late quarterly report notice, restructuring or exit costs in the last 12 months; operating loss: a margin of -6.6% in FY2026; free cash flow was negative: capital spending outran operating cash (-$12.8M in FY2026)
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $401.9M (FY2026), total debt $147.9M. Experience: revenue down 12.3% on the year, down 1.7% a year over 4 years; operating margin -6.6%, down from 1.7%. Soundness: equity 9.4% of assets, return on equity -118.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $312.6M and $420.9M next year (method v4.1: its own 5-year record of growth weighed at 57% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $290.0M to $455.1M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -6.6% against a 1.2% median; growth -12.3% against 11.6%.

Range logged 2026-10-07, receipt 6b73060c46191fee, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-08-06 ([filing](https://www.sec.gov/Archives/edgar/data/1138723/000143774926026250/0001437749-26-026250-index.htm))
- Item 4.02 Earlier statements no longer to be relied on: 1, latest 2026-02-09 ([filing](https://www.sec.gov/Archives/edgar/data/1138723/000143774926003515/0001437749-26-003515-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-02-09 ([filing](https://www.sec.gov/Archives/edgar/data/1138723/000143774926003517/0001437749-26-003517-index.htm))
- Item 2.05 Restructuring or exit costs: 1, latest 2025-12-16 ([filing](https://www.sec.gov/Archives/edgar/data/1138723/000119312525319896/0001193125-25-319896-index.htm))
- Item 5.02 Director or officer change: 8, latest 2026-10-13 ([filing](https://www.sec.gov/Archives/edgar/data/1138723/000143774926032558/0001437749-26-032558-index.htm))

## Recent filings

- 8-K · filed 2026-11-13 · 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1138723/000143774926036943/0001437749-26-036943-index.htm)
- 10-Q · filed 2026-11-06 · [filing](https://www.sec.gov/Archives/edgar/data/1138723/000143774926035560/0001437749-26-035560-index.htm)
- 8-K · filed 2026-11-04 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1138723/000143774926034951/0001437749-26-034951-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1138723/000143774926034929/0001437749-26-034929-index.htm)
- DEF 14A · filed 2026-10-16 · [filing](https://www.sec.gov/Archives/edgar/data/1138723/000114036126039918/0001140361-26-039918-index.htm)
- 8-K · filed 2026-10-13 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1138723/000143774926032558/0001437749-26-032558-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001138723.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1138723

## Cite

POPS4, Edgar & Edgarette: ACCURAY INCORPORATED (ARAY) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/ARAY. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

